NFE2L2 and chronic kidney disease: In human CKD patients, NRF2 protein levels correlate positively with renal function, and NRF2 activators such as bardoxolone methyl have demonstrated estimated GFR (eGFR) improvement in clinical trials, though safety concerns require careful patient selection [24,25,26].